Memantine for Enhanced Stroke Recovery (NCT02144584) | Clinical Trial Compass
Active — Not RecruitingEarly Phase 1
Memantine for Enhanced Stroke Recovery
United States20 participantsStarted 2014-01
Plain-language summary
This will be a randomized double blind placebo-controlled pilot study using a repeated measures design in which participants with acute ischemic stroke and upper extremity weakness are randomized to either drug or placebo
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age \>18 years old
✓. Randomization between 3 days-8 weeks days of stroke symptom onset
✓. Arm weakness severe enough to warrant inpatient or outpatient occupational therapies
✓. Able to voluntarily move affected UE
✓. Living independently prior to their stroke
✓. Image-confirmed ischemic stroke (MRI or CT)
✓. Supratentorial location of stroke
✓. Fugl-Meyer Upper Extremity Score of 50 or less and/or Fugl Meyer Lower Extremity Score of 28 or less
Exclusion criteria
✕. subarachnoid hemorrhage, subdural hemorrhage or other cause of symptoms other than ischemic or hemorrhagic stroke
✕. Infratentorial location of stroke (brainstem or cerebellum)
✕. NIH Stroke Scale \>20 at the time of randomization
✕. History of dementia that will interfere with rehabilitation
✕. Pre or post-stroke use of memantine or amantadine
✕. Contraindications to taking memantine XR in pill form
. History of prior clinical stroke with residual symptoms on the same side as the current symptoms that would interfere with outcomes of this study
✕. Documented severe renal impairment (CrCl \< 30 ml/min) Blood tests will be performed prior to study procedures that will ensure patients do not have renal impairment if not done as part of clinical care.